Diclofenac

證據等級: L5

預測適應症: 10 個

Diclofenac: From Inflammatory Pain to Juvenile Idiopathic Arthritis

One-Sentence Summary

Diclofenac is a non-selective COX-1/2 inhibitor (NSAID) established for pain and inflammatory conditions worldwide, though formal US license data was not captured in this Evidence Pack. The TxGNN model identifies Juvenile Idiopathic Arthritis (JIA) as the highest-evidence repurposing candidate among the 10 predictions evaluated, supported by 2 clinical trials and 18 publications — including direct clinical trials of diclofenac in paediatric arthritis dating from the 1980s. It is important to note that the model’s top-ranked predictions (ranks 1–8) are all rare genetic diseases with no supporting evidence and are flagged as likely knowledge graph false positives; JIA (rank 9) is the only actionable candidate in this pack.

Quick Overview

Item	Content
Original Indication	Inflammatory pain and musculoskeletal conditions (US license data not retrieved — see data gap note)
Predicted New Indication	Juvenile Idiopathic Arthritis
TxGNN Prediction Score	99.25%
Evidence Level	L2
US Market Status	Not captured (data gap — likely US-approved; see market section)
Number of NDAs	0 retrieved (data gap)
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Diclofenac is a non-selective cyclooxygenase inhibitor that blocks both COX-1 and COX-2, thereby suppressing prostaglandin biosynthesis. While the Evidence Pack did not retrieve formal MOA data from DrugBank (data gap DG002), the drug’s mechanism is described consistently in the evidence literature: COX inhibition reduces prostaglandin E2 (PGE2) production, which is the common mediator of pain, fever, and inflammatory tissue responses.

Juvenile Idiopathic Arthritis is characterised by synovial inflammation in which COX-2 overexpression drives excess PGE2 generation, directly causing joint swelling, pain, and fever. Diclofenac’s mechanism maps precisely onto this pathological axis. Crucially, this is not a speculative connection — the paediatric rheumatology literature from the 1980s already includes direct head-to-head clinical trials of diclofenac vs. naproxen and tolmetin in juvenile chronic arthritis, with comparable efficacy demonstrated across all three agents. Multiple subsequent reviews cite diclofenac as a standard first-line NSAID option for JIA.

By contrast, the model’s top-8 predictions (ranks 1–8, scores 99.25–99.69%) cover rare genetic conditions such as hypotrichosis simplex, acromesomelic dysplasia, pseudoachondroplasia, and WHIM syndrome — diseases caused by structural gene mutations (LPAR6, CDMP1/GDF5, COMP, CXCR4, etc.) with no known connection to the COX/prostaglandin pathway. These predictions most likely arise from network proximity artefacts in the knowledge graph rather than genuine biological signal. JIA stands apart as the only prediction with both mechanistic coherence and clinical validation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00688545	N/A (Observational Registry)	Terminated	275	SINCERE Registry: prospective multi-centre safety study comparing NSAIDs (including diclofenac) vs. celecoxib in JIA patients treated in clinical practice. Terminated early at 275 patients; provides real-world safety reference data but limited efficacy evidence due to observational design.
NCT05871086	Phase 2/3	Unknown	60	Coenzyme Q10 supplementation in JIA (2023); NSAIDs cited as standard background therapy but are not the study intervention. Indirect relevance only — confirms current NSAID use in JIA practice.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
3052965	1988	RCT (crossover)	Clinical and Experimental Rheumatology	Single-blind crossover trial in 28 children with seronegative JCA comparing naproxen (10 mg/kg/day), diclofenac (2 mg/kg/day), and tolmetin (25 mg/kg/day) over 12 weeks; all three showed comparable clinical and laboratory efficacy with similar tolerability.
6361986	1983	Clinical Trial	Scandinavian Journal of Rheumatology	Direct pharmacokinetic and clinical study of diclofenac sodium in juvenile rheumatoid arthritis; assessed plasma levels and renal elimination in children aged 2–7, providing foundational paediatric dosing data.
2235663	1990	Clinical Study	Pediatria Medica e Chirurgica	Open non-comparative study of diclofenac sodium in 26 patients (aged 2–16) with polyarticular juvenile chronic arthritis; confirmed anti-inflammatory and analgesic effects consistent with adult data.
10756785	1997	Comparative Study	Revista Medico-Chirurgicala	Eight-year comparative study of diclofenac vs. ibuprofen vs. aspirin in 100 children with JCA; evaluated clinical and laboratory outcomes at multiple time points up to 3 years of follow-up.
8422565	1993	Review	British Journal of Rheumatology	Comprehensive review of NSAID use in paediatric rheumatic diseases; explicitly states diclofenac, ibuprofen, tolmetin, and naproxen are equal in efficacy and tolerability for JCA joint symptom control; aspirin and indomethacin are more toxic without added benefit.
11735667	2001	Review (Risk-Benefit)	Paediatric Drugs	Risk-benefit analysis of NSAIDs in children including JIA and Kawasaki disease; covers COX inhibition mechanism, paediatric pharmacokinetics, and safety profile including GI, renal, and bleeding risks.
1884567	1991	PK Study	Clinical Pharmacokinetics	Pharmacokinetic review of drugs used in juvenile arthritis, including NSAIDs; provides dosing rationale and metabolic considerations relevant to diclofenac use in the paediatric JIA population.
17474954	2007	Survey	Paediatric Anaesthesia	UK/Ireland survey noting that diclofenac is licensed for children over 1 year for juvenile rheumatoid arthritis treatment; highlights paediatric NSAID licensing landscape.
723822	1978	Clinical Study	Minerva Pediatrica	One of the earliest clinical studies of sodium diclofenac in infantile rheumatoid arthritis, establishing initial paediatric safety and efficacy signal.
6761640	1982	Clinical Study	Pediatriia	Soviet clinical study of Voltaren (diclofenac) in children with rheumatoid arthritis; corroborates efficacy findings from Western paediatric rheumatology literature.

US Market Information

No US market authorizations were retrieved for Diclofenac in this Evidence Pack (market status recorded as “未上市,” 0 NDAs). This is very likely a data retrieval gap rather than a true absence: diclofenac is approved in the United States under multiple brand names (e.g., Voltaren Gel, Zipsor, Cambia, Pennsaid) across both oral and topical formulations.

Manual verification against the FDA Orange Book is recommended before relying on the market status recorded here. The data gap DG001 (TFDA package insert) and the US market retrieval failure should both be resolved before proceeding to formal safety evaluation.

Safety Considerations

Please refer to the package insert for safety information.

All safety fields in this Evidence Pack are marked as data gaps (DG001). Standard NSAID class warnings — including GI bleeding risk, renal impairment, cardiovascular risk, and contraindication in third-trimester pregnancy — apply and must be retrieved from the official labelling before any clinical decision is made.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The JIA repurposing direction is mechanistically coherent (COX-mediated synovial inflammation) and is clinically validated by direct paediatric clinical trials spanning four decades — including at least one randomised crossover study. In practice, this may represent the TxGNN model correctly recovering an established (though perhaps unlabelled) indication rather than a genuinely novel repurposing discovery, which itself validates the model’s predictive signal for this drug class.

To proceed, the following is needed:

Resolve US market status: Retrieve NDAs from the FDA Orange Book manually; the “未上市” in this pack is almost certainly a data gap for a globally established drug
Retrieve DrugBank MOA data (DG002): Formally confirm COX-1/2 inhibition profile and any additional pharmacological targets for the evidence file
Retrieve package insert warnings and contraindications (DG001): Required to complete the S1 safety evaluation; standard NSAID risks (GI, renal, cardiovascular) are expected to apply
Clarify indication status: Determine whether JIA is already a formally approved indication for diclofenac in the US (in which case this is indication-label confirmation rather than repurposing, and regulatory strategy differs accordingly)
Review ranks 1–8 false positive pattern: All 8 top-scored predictions are rare genetic diseases with no COX-pathway connection; this warrants a calibration review of the TxGNN model’s knowledge graph for this drug to assess systematic bias in scoring
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.